[go: up one dir, main page]

AU2001278084A1 - Model for alzheimer's disease and other neurodegenerative diseases - Google Patents

Model for alzheimer's disease and other neurodegenerative diseases

Info

Publication number
AU2001278084A1
AU2001278084A1 AU2001278084A AU7808401A AU2001278084A1 AU 2001278084 A1 AU2001278084 A1 AU 2001278084A1 AU 2001278084 A AU2001278084 A AU 2001278084A AU 7808401 A AU7808401 A AU 7808401A AU 2001278084 A1 AU2001278084 A1 AU 2001278084A1
Authority
AU
Australia
Prior art keywords
alzheimer
disease
model
neurodegenerative diseases
neurodegenerative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278084A
Inventor
Xiaoning Bi
Gary Lynch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley filed Critical University of California
Publication of AU2001278084A1 publication Critical patent/AU2001278084A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2001278084A 2000-07-31 2001-07-31 Model for alzheimer's disease and other neurodegenerative diseases Abandoned AU2001278084A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22206000P 2000-07-31 2000-07-31
US60/222,060 2000-07-31
US28335201P 2001-04-13 2001-04-13
US60/283,352 2001-04-13
PCT/US2001/023894 WO2002010768A2 (en) 2000-07-31 2001-07-31 Model for alzheimer's disease and other neurodegenerative diseases

Publications (1)

Publication Number Publication Date
AU2001278084A1 true AU2001278084A1 (en) 2002-02-13

Family

ID=26916406

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278084A Abandoned AU2001278084A1 (en) 2000-07-31 2001-07-31 Model for alzheimer's disease and other neurodegenerative diseases

Country Status (5)

Country Link
US (2) US6803233B2 (en)
EP (1) EP1315971A2 (en)
AU (1) AU2001278084A1 (en)
CA (1) CA2417744A1 (en)
WO (1) WO2002010768A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407663B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
US7407662B2 (en) 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
US7439052B2 (en) 2000-06-29 2008-10-21 Lipid Sciences Method of making modified immunodeficiency virus particles
US6803233B2 (en) 2000-07-31 2004-10-12 The Regents Of The University Of California Model for Alzheimer's disease and other neurodegenerative diseases
AU2001288792A1 (en) * 2000-09-06 2002-03-22 Neurotherapeutics, Llc Method of treating neurologic disorders
EP1326997A4 (en) * 2000-09-25 2006-01-11 Univ Model for neurodegenerative diseases involving amyloid accumulation
WO2002067764A2 (en) 2001-02-27 2002-09-06 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation
US20060060520A1 (en) 2001-06-25 2006-03-23 Bomberger David C Systems and methods using a solvent for the removal of lipids from fluids
US6991727B2 (en) 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US7033500B2 (en) 2001-06-25 2006-04-25 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
KR20050083971A (en) * 2002-11-22 2005-08-26 더 존스 홉킨스 유니버시티 Target for therapy of cognitive impairment
US20060014801A1 (en) * 2002-11-22 2006-01-19 The Johns Hopkins University Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs
AU2004212944B2 (en) * 2003-02-14 2008-08-21 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
AU2004260632A1 (en) 2003-07-03 2005-02-10 Lipid Sciences Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US20050282883A1 (en) * 2004-04-29 2005-12-22 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20060084695A1 (en) * 2004-04-29 2006-04-20 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7199126B2 (en) 2004-04-29 2007-04-03 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7163945B2 (en) * 2004-04-29 2007-01-16 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050272770A1 (en) * 2004-04-29 2005-12-08 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20060111436A1 (en) * 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
US20100087474A1 (en) * 2005-04-27 2010-04-08 University Of Florida Materials and methods for enhanced degradation of mutant proteins associated with human disease
WO2007003941A1 (en) * 2005-07-06 2007-01-11 Cambridge Enterprise Limited Modulation of autophagy by calpain inhibition
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
EP1795895A1 (en) * 2005-12-08 2007-06-13 KeyNeurotek AG A tissue-based assay system for Alzheimer-specific degeneration and pathology
JP2010526645A (en) 2007-05-11 2010-08-05 クラリメディックス・インコーポレイテッド Visible light regulation of mitochondrial function in hypoxia and disease
US20110064721A1 (en) * 2007-07-12 2011-03-17 The Uab Research Foundation Cathepsin-d neuroprotection
WO2009040024A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2009158678A1 (en) 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use therefor
EP3586839A1 (en) 2008-07-28 2020-01-01 Blanchette Rockefeller Neurosciences, Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
JP2011529344A (en) 2008-07-28 2011-12-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート Stimulation-induced genomic profile markers for Alzheimer's disease
US20110312059A1 (en) * 2008-08-20 2011-12-22 Oligomerix Inc. Tau protease compositions and methods
US20120003655A1 (en) * 2008-12-03 2012-01-05 The Salk Institute For Biological Studies Identification of neuroprotective agents using pro-inflammatory human glial cells
EP2419100A4 (en) * 2009-04-14 2013-07-17 Kim Nicholas Green Method of decreasing pro-adam10 secretase and/or beta secretase levels
US20110144029A1 (en) * 2009-09-30 2011-06-16 Board Of Regents, The University Of Texas System Model Systems and Materials for the Study and Treatment of Neurodegenerative Diseases
CN102741693A (en) * 2009-10-02 2012-10-17 布朗歇特洛克菲勒神经科学研究所 Fibroblast growth patterns for diagnosis of alzheimer's disease
EP2720692A4 (en) * 2011-06-17 2015-05-20 Virobay Inc Cathepsin inhibitors for treating microglia-mediated neuron loss in the central nervous system
US9163032B2 (en) 2011-11-13 2015-10-20 Blanchette Rockefeller Neurosciences Insitute Esters of DCPLA and methods of treatment using the same
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
CN104458709A (en) * 2013-09-12 2015-03-25 中国药科大学 High flux screening method for screening calcium activated neutral protease-1 inhibitor
AU2018372198A1 (en) 2017-11-22 2020-06-11 Hdl Therapeutics, Inc. Systems and methods for priming fluid circuits of a plasma processing system
JP2021509894A (en) 2017-12-28 2021-04-08 エイチディーエル セラピューティクス インコーポレイテッドＨｄｌ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Methods for Preserving and Administering Pre-β High Density Lipoprotein Extracted from Human Plasma
CN113244402B (en) * 2021-05-27 2022-11-18 山西医科大学 Application of P-ERK signal channel in inhibiting tau protein abnormal phosphorylation and cytotoxicity caused by aluminum

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340922B1 (en) * 1988-05-31 1999-11-02 Mclean Hospital Corp Neural calcium-activated neutral proteinase inhibitors
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5444042A (en) * 1990-12-28 1995-08-22 Cortex Pharmaceuticals Method of treatment of neurodegeneration with calpain inhibitors
CA2111870A1 (en) * 1991-06-21 1993-01-07 Robert W. Colman Calpain-inhibiting peptide analogs of the kininogen heavy chain
JP3228347B2 (en) * 1991-06-25 2001-11-12 三菱化学株式会社 Cyclopropenone derivative
JP3190431B2 (en) * 1991-07-01 2001-07-23 三菱化学株式会社 Ketone derivatives
AU2414092A (en) * 1991-08-01 1993-03-02 Paul H. Voorheis Diagnostic method for alzheimer's disease
CA2086165A1 (en) * 1992-04-09 1993-10-10 Paul P. Tamburini Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein
JPH0641067A (en) * 1992-04-20 1994-02-15 Kitasato Inst:The New calpain-inhibitor kp-1241 and its production
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5621101A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5395958A (en) * 1992-09-30 1995-03-07 Mitsubishi Kasei Corporation Cyclopropene derivatives
EP0603769B1 (en) * 1992-12-25 1998-09-16 Mitsubishi Chemical Corporation Alpha-Aminoketone derivatives
CA2111930A1 (en) * 1992-12-25 1994-06-26 Ryoichi Ando Aminoketone derivatives
JP2848232B2 (en) * 1993-02-19 1999-01-20 武田薬品工業株式会社 Aldehyde derivatives
US5622967A (en) * 1993-04-26 1997-04-22 Sterling Winthrop, Inc. Quinolone carboxamide Calpain inhibitors
JP3599287B2 (en) * 1993-04-28 2004-12-08 三菱化学株式会社 Sulfonamide derivative
US5554767A (en) * 1993-05-21 1996-09-10 Warner-Lambert Company Alpha-mercaptoacrylic acid derivatives having calpain inhibitory activity
NO941915L (en) * 1993-05-25 1994-11-28 Daiichi Seiyaku Co Medicine for nerve protection
AU6836394A (en) * 1993-06-01 1994-12-20 Cortex Pharmaceuticals, Inc. Use of metabotropic receptor agonists in progressive neurodegenerative deseases
US5541290A (en) * 1993-06-24 1996-07-30 Harbeson; Scott L. Optically pure calpain inhibitor compounds
FR2713644B1 (en) * 1993-12-14 1996-02-09 Adir New analogs of eburnane, process for their preparation and pharmaceutical compositions containing them.
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
US5686269A (en) * 1994-07-28 1997-11-11 The Mclean Hospital Corporation Method of diagnosing Alzheimer's disease by detecting the level of cathepsin D in cerebrospinal fluid
US5498616A (en) * 1994-11-04 1996-03-12 Cephalon, Inc. Cysteine protease and serine protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5691368A (en) * 1995-01-11 1997-11-25 Hoechst Marion Roussel, Inc. Substituted oxazolidine calpain and/or cathepsin B inhibitors
US5679680A (en) * 1995-02-16 1997-10-21 Warner-Lambert Company α-substituted hydrazides having calpain inhibitory activity
EP0820464A2 (en) 1995-03-31 1998-01-28 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US5654146A (en) * 1995-05-31 1997-08-05 Incyte Pharmaceuticals, Inc. Human ice homolog
US5849711A (en) * 1995-06-06 1998-12-15 Athena Neurosciences, Inc. Cathepsin and methods and compositions for inhibition thereof
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors
US6177472B1 (en) * 1995-08-08 2001-01-23 University Of Alabama At Birmingham Research Foundation Regulation of alzheimer's disease proteins and uses thereof
US5849691A (en) * 1996-02-20 1998-12-15 The United States Of America As Represented By The Department Of Health And Human Services Peptidomimetic inhibitors of cathepsin D and plasmepsins I and II
US6447988B2 (en) * 1997-01-22 2002-09-10 The Regents Of The University Of California In vitro assay method for the study of brain aging
AU6245798A (en) * 1998-01-08 1999-07-26 Regents Of The University Of California, The Brain aging assay
WO2000021550A2 (en) 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methods and compositions for treating neurodegenerative diseases
AU1092600A (en) 1998-10-15 2000-05-01 Canji, Inc. Calpain inhibitors and their applications
US6288089B1 (en) * 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
EP1026251A3 (en) * 1999-02-03 2000-09-06 Pfizer Products Inc. Transgenic animals expressing human P25
WO2001053340A2 (en) 2000-01-21 2001-07-26 Pharmacia & Upjohn Company Transgenic mouse model of human neurodegenerative disease
US6803233B2 (en) * 2000-07-31 2004-10-12 The Regents Of The University Of California Model for Alzheimer's disease and other neurodegenerative diseases
EP1326997A4 (en) 2000-09-25 2006-01-11 Univ Model for neurodegenerative diseases involving amyloid accumulation
US20020094958A1 (en) * 2000-10-30 2002-07-18 Bahr Ben A. Materials for lysosome modulation and methods of use thereof

Also Published As

Publication number Publication date
US20040229209A1 (en) 2004-11-18
CA2417744A1 (en) 2002-02-07
WO2002010768A2 (en) 2002-02-07
US6803233B2 (en) 2004-10-12
EP1315971A2 (en) 2003-06-04
WO2002010768A3 (en) 2003-01-03
US20020048746A1 (en) 2002-04-25
WO2002010768A9 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
AU2001278084A1 (en) Model for alzheimer's disease and other neurodegenerative diseases
AU2002219824A1 (en) Compositions and methods for diagnosing alzheimer's disease
AU2001233299A1 (en) Methods for treating alzheimer's disease
AU2001273132A1 (en) Compounds to treat alzheimer's disease
AU7708498A (en) Nematode model for alzheimer's disease
AU2001249835A1 (en) Diagnosis and treatment of alzheimer's disease
AU1407399A (en) Treatment for alzheimer's disease
AU2865000A (en) Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease
AU2610901A (en) Predictive diagnostic for alzheimer's disease
AU2002363825A1 (en) Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases
AU2001236592A1 (en) Methods for diagnosis of alzheimer's disease
AU2002239765A1 (en) Antibody pti-hs7 for treatment of alzheimer's disease and other amyloidoses and parkinson's disease
AU2001229619A1 (en) Transgenic mouse model of human neurodegenerative disease
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
AU2001273661A1 (en) Methods of screening for alzheimer's disease
AU1280799A (en) Non-transgenic animal model of alzheimer's disease
AU2003209301A1 (en) Treatments for neurotoxicity in alzheimer's disease
AU2002359781A1 (en) Triple transgenic mouse model of alzheimer's disease
AU2002222156A1 (en) Human protein differentially expressed in alzheimer's disease's brain
AU2001248760A1 (en) Preventives/remedies for alzheimer's disease
AU1405899A (en) Treatment for alzheimer's disease
AU2001289834A1 (en) Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders
AU2002312667A1 (en) Individualization of therapy with alzheimer's disease agents
AU2001267826A1 (en) Remedies for alzheimer's disease
AU2002364885A1 (en) Alzheimer's disease model